According to the latest market study carried out worldwide by the consulting firm Apex Market Research, the technology multinational GMV It is among the Top 10 in intraoperative radiotherapy (IOR), standing out in the category of innovative company. Companies with this classification correspond to those suppliers that have demonstrated substantial innovations in their products compared to their competitors.
GMV has been highlighted by Apex in the innovative company classification, thanks to Radiance, and is among the top 10 for intraoperative radiotherapy
Intraoperative radiotherapy is a high precision technique in which a single, high fraction of radiotherapy is administered during a surgical procedure, on the tumor bed / microscopic residue, or on the macroscopic tumor, in the case of unresectable tumors. With it, the bed to be irradiated is directly visualized, leaving the surrounding healthy tissues outside the irradiation field.
The increasing incidence of cancer, technological advances and the advantages offered by intraoperative radiotherapy applications are the main factors that are driving the growth of the global market. The consulting firm foresees in its study that intraoperative radiotherapy will reach $ 67.8 million in 2024, growing at an annual rate of 7% from 2019 to 2024. GMV is among the world leaders thanks to its intraoperative radiotherapy planner called Radiance and to its commercial alliances with other market leaders such as Carl Zeiss, Meditec AG (Germany) and IntraOp Medical Corporation (USA).
The global intraoperative radiotherapy market will reach $ 67.8 million in 2024, with a growth forecast of 7% from 2019 to 2024
Radiance is the only radiosurgical planner on the market
Radiance improves the safety of intraoperative radiation therapy (IOR). It facilitates the specialist the complete analysis of the patient and the decision-making prior to the surgical intervention. It does so by identifying the optimal treatment for each of them, personalized and translational medicine.
Its innovative software offers all the necessary data to document the intervention. Calculate the exact parameters required to apply radiotherapy in the operating room itself, before the surgical act. It provides high quality multiplanar images (MPR) and three-dimensional (3D) vision of the patient, allowing simulated visualization of the treatment result.
Likewise, by optimizing treatment, making it more efficient, effective, safe and specific, it contributes to the sustainability of the health system. On the one hand, because the radiation is done directly in the operating room itself, after resection of the tumor, ensuring the precision of the result. On the other hand, because no subsequent radiotherapy sessions have to be performed. Today, three out of every 10 patients who require radiotherapy do not receive it, either due to lack of equipment or due to geographic dispersion. There are cases of patients who have to do 200 kilometers every day to receive radiotherapy treatment. This situation could be alleviated by applying intraoperative radiotherapy at the time of the intervention.
Radiance reduces the risk of recurrence in various types of tumors and its palliative value is important in other types of cancers that are difficult to cure.
Furthermore, the technique followed by Radiance reduces the risk of recurrence in various types of tumors (for example brain tumors, rectal cancer, sarcomas or breast cancer), and its palliative value is important in other types of cancers that are difficult to cure, such as cancer of the pancreas or in cases of recurrence of the oncological process.
Intraoperative radiotherapy has several benefits, including saving the patient from trips to the hospital during the duration of the treatment, usually three to five weeks depending on the type of tumor. This affects an improvement both physical and psychological and quality of life of the individual. The patient thus benefits from less hospital attendance; less treatment sessions with external radiotherapy in some cases (for example, early breast cancers, with favorable prognostic factors), and at the same time it is possible to minimize side effects on surrounding healthy tissues. The most recent publication of the long-term results (12 years of follow-up) of the Targit clinical trial shows a lower mortality rate from diseases not related to the tumor treated.
Radiance is present in different Spanish entities such as the Doctor Negrín University Hospital of Gran Canaria (Las Palmas) or the Provincial Hospital (Castellón). As well as the Hospital de La Luz (Madrid), the Hospital Gregorio Marañón (Madrid), the Hospital Central de Asturias or the Hospital Virgen de la Arrixaca.